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Intussusception is a rare, potentially life-threatening 
condition in early childhood. It gained attention due to 
an unexpected association with the first rotavirus vac-
cine, RotaShield, which was subsequently withdrawn 
from the market. Across Europe, broad variations in 
intussusception incidence rates have been reported. 
This study provides a first estimate of intussusception 
incidence in young children in the Netherlands from 
1 January 2008 to 31 December 2012, which could be 
used for future rotavirus safety monitoring. Our esti-
mates are based on two different sources: electronic 
medical records from the primary healthcare database 
(IPCI), as well as administrative data from the Dutch 
hospital register (LBZ). The results from our study 
indicate a low rate of intussusception. Overall inci-
dence rate in children < 36 months of age was 21.2 per 
100,000 person-years (95% confidence interval (CI): 
12.5–34.3) based on primary healthcare data and 22.6 
per 100,000 person-years (95% CI: 20.9–24.4) based 
on hospital administrative data. The estimates sug-
gest the upper and lower bound of the expected num-
ber of cases.
Introduction
Rotavirus infections are a leading cause of severe 
diarrhoeal illness in infants and young children [1]. As 
demonstrated by a number of studies, rotavirus vac-
cines are effective in preventing severe diarrhoeal ill-
ness caused by certain rotavirus serotypes [2,3]. In 
1999 however, the first rotavirus vaccine, RotaShield 
(Wyeth Laboratories, Inc., Pennsylvania, United 
States), was voluntarily withdrawn from the market 
due to an unexpected association with intussusception 
[4]. Intussusception is a serious condition that can be 
described as the invagination of a proximal segment of 
the bowel into the distal bowel. If left untreated, the 
blood flow can become compromised, leading to bowel 
infarction and perforation. In 2006, two second gen-
eration rotavirus vaccines, Rotarix (GlaxoSmithKline 
Biologicals, Rixensart, Belgium) and RotaTeq (MSD 
vaccines, Lyon, France), were approved for market-
ing in Europe. In 2009, the World Health Organization 
Strategic Advisory Group of Experts (SAGE) recom-
mended the use of rotavirus vaccines in all national 
immunisation programs, and by 2016, 11 countries of 
the European Union had included rotavirus vaccination 
in their national vaccination programme [5]. Although 
large-scale pre-licensure clinical trials did not identify 
an increased risk for intussusception, post-licensure 
data suggested a small increase in risk of intussuscep-
tion that was closely linked to the age of vaccination 
after rotavirus vaccination with both licensed vaccines 
[6-11].
The aetiology of primary intussusception in young chil-
dren remains unclear. Intussusception is most common 
between 5 and 7 months of age [12]. Approximately 
60% to 75% of children diagnosed with intussuscep-
tion are younger than 1 year of age, and approximately 
80% to 90% are younger than 2 years of age. Most epi-
sodes occur in otherwise healthy children with a male 
to female predominance of ca 3:2 [13].
Ultrasonography is the method of choice to detect 
intussusception. Ultrasound-guided reduction using 
hydrostatic or pneumatic pressure by enema is the 
treatment of choice. Surgical treatment is indicated 
when ultrasound-guided reduction is incomplete or in 
case perforation is suspected.
Sentiments towards the importance of vaccination in 
general are positive overall but confidence in vaccine 
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safety is less positive, particularly in the European 
region [14]. In the Netherlands, where the impact of 
rotavirus vaccine is considered modest [15], concerns 
about vaccine safety may lead to vaccine hesitancy and 
decreased vaccination coverage for vaccine-preventa-
ble diseases in general [16]. Knowledge of the back-
ground incidence rates of possible adverse events is a 
crucial part of assessing possible vaccine safety con-
cerns. It allows for a rapid observed vs expected analy-
sis and helps to distinguish legitimate safety concerns 
from events that are temporally associated with but 
not necessarily caused by vaccination [17]. In the case 
of rotavirus vaccination, it is important to know the 
background incidence of intussusception. Studies in 
Europe have reported incidence rates of intussuscep-
tion between 24.2 and 60.4 per 100,000 person-years 
[18-23] and show a decline over time [19,22]. Methods 
used to estimate these incidence rates differ in age of 
source population, length of study period, and detec-
tion and validation of cases.
To date, the use of rotavirus vaccines in the Dutch 
population can be considered negligible. Rotavirus 
vaccines are not included in the Dutch national vacci-
nation programme, are not recommended for routine 
use and are not reimbursed by the health insurance. To 
support future rotavirus vaccine safety surveillance in 
the event that rotavirus vaccine would be introduced in 
the Dutch national vaccination programme, this study 
aims to calculate the baseline incidence rates of intus-
susception in the Netherlands.
Methods
Data sources
For this study two different data sources that capture 
a partially overlapping source population were used: 
an administrative hospital discharge database and a 
primary healthcare database. Administrative hospital 
discharge data were obtained from the Dutch hospi-
tal register, Landelijke Basisregistratie Ziekenhuiszorg 
(LBZ). Hospitals and university medical centres in the 
Netherlands have a legal and statutory obligation to 
collect and provide electronic administrative data to 
the LBZ database on a monthly basis. The LBZ data-
base covers more than 80% of the total Dutch popula-
tion of 17 million people. It contains anonymised data 
on hospital admissions, outpatient consultation and 
emergency department visits including medical diag-
noses, as well as patient-specific data such as age and 
sex [24]. Coding of discharge diagnoses is performed 
by participating hospitals according to the International 
Classification of Diseases, Ninth Revision (ICD-9) [25]. 
A validation study showed high accuracy of coding and 
concluded that the discharge data are generally of high 
quality [26].
The second source was a primary healthcare database, 
the Integrated Primary Care Information (IPCI) data-
base. IPCI is a longitudinal observational database 
Figure 1
Intussusception incidence rate in children < 36 months of 
age per 100,000 person-years by age and data source, the 
Netherlands, 1 January 2008–31 December 2012
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Figure 2
Intussusception incidence rate in children < 36 months of 
age per 100,000 person-years by year and data source, the 
Netherlands, 1 January 2008–31 December 2012
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created specifically for pharmaco-epidemiological 
studies [27]. It contains anonymised data, includ-
ing notes from computer-based medical records of 
around 600 general practitioners (GPs) located in the 
Netherlands. IPCI contains information on more than 
1.1 million patients from over 200 participating GP 
practices. The age and sex distribution of the popula-
tion is representative for the Netherlands. In the Dutch 
healthcare system, the GP acts as a gatekeeper for all 
medical care. It is estimated that more than 75% of the 
Dutch population in the age group 0–3 years will visit 
their GP at least once per year [28]. In the event intus-
susception is suspected, the patient will be referred to 
hospital for confirmation and treatment. Following con-
sultation at the hospital, it is standard practice to for-
ward the details of the consultation and the outcome 
to the GP. In the rare event a patient by-passes the GP, 
the hospital will also forward the details of the consul-
tation and the outcome to the patient’s GP. Therefore, 
patients’ medical records at GP practices are likely to 
contain all relevant medical information.
Study design and population
Cases were retrieved differently from the two data 
sources. From the LBZ hospital discharge database, all 
cases with a primary or secondary discharge diagnosis 
of intussusception (ICD-9 CM code 560.0) in children 
aged between 0 and 36 months (i.e. children aged 0–35 
months) at admission were retrieved for the period 
from 1 January 2008 to 31 December 2012. Cases with a 
secondary diagnosis of intussusception were reviewed 
by a paediatrician to determine whether the combined 
set of ICD codes for the admission was compatible with 
a new occurrence of intussusception, taking comorbidi-
ties, patient age and primary discharge diagnosis into 
account. Possible duplicate reports because of patient 
transfers were identified based on sex, birthdate and 
date of diagnosis, and were excluded.
Based on the data captured by IPCI, we constructed a 
dynamic cohort. Initially, we attempted to assess the 
incidence rate over a period of 10 years, from 1 January 
2003 to 31 December 2012. However, the addition 
of many new practices to the IPCI database in 2007 
caused the observation time to vary considerably over 
the course of the 10-year study period and we subse-
quently restricted the analysis to a period of 5 years, 
from 1 January 2008 to 31 December 2012. This yielded 
a more stable population (Table 1).
We only selected children who were born during the 
study period and who had contributed longitudi-
nal data to the IPCI database from birth onwards. 
Follow-up started from birth and continued until the 
date the patient became a case, the patient reached 
the age of 36 months, the patient died, the patient 
was transferred out of the GP’s practice, the date of 
last data collection from the general practice or the 
end of the study period was reached, whichever date 
came first. In the IPCI database, cases were identified 
by automated scanning of keywords in GPs’ notes in 
the medical records. The complete medical records of 
all potential cases were reviewed by a medical doctor 
for details alluding to additional diagnostic procedures 
or received treatment. An identified case was consid-
ered a true case if the medical journal of that particular 
patient contained results from ultrasound examination 
Figure 3
Intussusception incidence rate in children < 12 months 
of age per 100,000 person-years by age category and year 
based on non-validated cases from the LBZ database, the 
Netherlands, 1 January 2008–31 December 2012
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Table 1
Incidence rate of intussusception per 100,000 person-years 
based on validated cases from the Integrated Primary 
Care Information (IPCI) database, the Netherlands, 
January 2003–December 2012
Year Cases (n)
Person time 
(person-years)
Incidence rate 
per 100,000 
person-years
95% CI
2003 0 2,226 NA NA
2004 1 2,323 43.0 3.9–200.7
2005 0 4,549 NA NA
2006 0 978 NA NA
2007 0 1,495 NA NA
2008 2 4,045 49.4 9.9–158.5
2009 2 8,435 23.7 4.7–76.0
2010 4 14,087 28.4 9.5–67.5
2011 2 19,326 10.3 2.1–33.2
2012 5 24,649 20.3 7.7–44.5
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confirming the diagnosis and/or details regarding 
receiving treatment specific for intussusception such 
hydrostatic reduction. Cases with an actual diagno-
sis of intussusception were subsequently classified 
by level of evidence using the web-based Automated 
Brighton Collaboration Case definition tool (ABC-tool) 
for intussusception. Level one corresponds to the high-
est level of diagnostic evidence and level three corre-
sponds to the lowest [29]. We subsequently compared 
LBZ and IPCI data for those years where comparable 
data were available.
Analysis
Age-specific incidence rates were calculated from data 
in each of the two data sources using the number of 
intussusception cases from that source as a numera-
tor and the study population as denominator. Since 
dominator data are not available in the LBZ database, 
approximate denominators based on national popula-
tion data from Statistics Netherlands (CBS) were used, 
assuming that 80% of the population would be cov-
ered in the LBZ database [30]. In the IPCI database, the 
underlying study cohort could be well defined in terms 
of the number of person-years of follow-up of patients. 
Incidence rates of intussusception were calculated by 
dividing the number of incident intussusception cases 
by the total number of person-years. Incidence rates 
were calculated by calendar year, age category and 
sex. Confidence intervals (95% CI) for each estimate 
were based on the Poisson distribution.
Results
Landelijke Basisregistratie Ziekenhuiszorg 
(LBZ) database
In the LBZ database, 705 potential cases of intussus-
ception were identified during the study period and 
166 duplicate cases were excluded. Based on the 
remaining 539 identified cases of intussusception, 
the overall crude incidence rate over the study period 
from 1 January 2008 to 31 December 2012 was 22.6 per 
100,000 person-years (95% confidence interval (CI): 
20.9–24.4). Figure 1 shows the age-specific incidence 
rates; the highest rate was observed in children < 12 
months of age.
The incidence rate remained constant over time (Figure 
2).
The incidence rate in children < 12 months of age varies 
considerably by age, but as is expected, the data show 
that is it more common after the age of three months 
(Figure 3).
Integrated Primary Care Information (IPCI) 
database
From the IPCI database, 155,880 children were included 
in the initial study cohort (Table 2). Within this popula-
tion, 131 potential cases were detected after a sensitive 
search for indicators of intussusception in narratives. 
We subsequently restricted age-specific analysis to the 
period from 1 January 2008 to 31 December 2012, which 
yielded a more stable population. In the period from 1 
January 2008 to 31 December 2012, the population com-
prised of 144,617 children. Following manual validation 
by a medical doctor, 15 cases (14 definite, 1 possible) 
were classified as incident intussusception (Table 1). 
When using the ABC-tool, all cases were classified as 
having insufficient information to meet the Brighton 
Collaboration case definition of intussusception. This 
was because none of the cases included any informa-
tion regarding one of the exclusion criteria: absence of 
surgical evidence for an alternative diagnosis. Based 
on the number of cases validated by a medical doctor, 
the crude incidence during the period 1 January 2008 
to 31 December 2012 was 21.2 per 100,000 person-
years (95% CI: 12.5–34.3). The incidence was higher in 
boys than in girls, and was highest in the lowest age 
category, subsequently decreasing with age (Table 3). 
Results per age category are provided in Figure 1, and 
overall incidence per calendar year in Figure 2.
Discussion
This study showed that background incidence rates 
of intussusception can be estimated using routinely 
collected healthcare data. The intussusception inci-
dence rate in children < 12 months of age is 27.9 per 
100,000 person-years (95% CI: 14.3–49.5) based on 
cases from the primary healthcare data that were vali-
dated, and 35.0 per 100,000 person-years (95% CI: 
31.3–39.0) based on the non-validated hospital data. 
TABLE 2
Study cohort details for investigation of intussusception incidence rates using the IPCI database, the Netherlands, 1 January 
2008–31 December 2012
Study cohort
Time period
1 Jan 2003–31 Dec 2012 1 Jan 2008–31 Dec 2012
Study population (n) 155,880 144,617
Person time of follow up (person-years) 82,113 70,542
Number of intussusception cases (n) 16 15
IPCI: Integrated Primary Care Information.
The IPCI database contains general practitioner medical records.
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These estimates are on the lower end of published 
incidences across Europe. Consistent with previous 
research [19,22,23,31], the incidence rate in boys was 
higher than in girls, and was highest in the youngest 
age group.
When comparing the intussusception incidence rates 
derived from the IPCI primary healthcare database 
with those derived from the LBZ hospital database, the 
results from the IPCI database are validated but less 
precise, and possibly an underestimation. From the 
hospital database, we were able to derive precise inci-
dence rates for smaller age categories. However, the 
coding could not be validated and the incidence rate 
may possibly be an overestimation. A declining trend 
over time was not evident. The true intussusception 
rate is likely to be in between the estimates derived 
from the primary healthcare database and the hospital 
database. The advantage of this dual approach is that 
interpreting the occurrence of future cases after vacci-
nation may be done with or without validation, and we 
have provided an assessment of the impact thereof.
The advantage of using a primary healthcare, GP-based 
database such as the IPCI was that case detection 
did not depend on the validity of coding as free text 
keyword searches, rather than codes, were used. The 
availability of medical notes in free text provided a 
rich source of information, enabling case ascertain-
ment. Although it would be interesting to know the 
composition of the participating practices, we were 
not able to identify any evidence that would suggest 
that the composition of the GP practice is a risk factor 
for intussusception. Therefore, we consider it unlikely 
that our estimate is biased by the composition of the 
GP practices. As a denominator, we were able to use 
accrued time since birth. However, intussusception is 
a condition typically diagnosed in a hospital setting. 
Although it is considered standard practice to forward 
all relevant hospital patient data to the GP, it cannot 
be ruled out that some hospital diagnoses were not 
communicated to GPs or were substantially delayed 
in terms of being reported back. Since the number of 
ascertained cases was small, we could only calculate 
the incidence for age categories of one year and the 
confidence intervals are rather large.
The majority of first-time rotavirus infections usually 
occur in infancy. In high income countries, 65% occurs 
in infants < 1 year of age [32]. Therefore, it is recom-
mended that rotavirus vaccination be administered 
before the age of 6 months. However, the reported inci-
dence of intussusception varies substantially by age 
during the first 6 months of life [23,33]. Age-specific 
incidence rates in months or even weeks of age would 
be very useful in terms of informing rotavirus vaccine 
safety policy; however, this would require a much 
larger cohort.
Because the administrative hospital database covers a 
larger population than the primary healthcare one, we 
were able to derive more precise incidence rates and 
incidence rates for smaller age categories. Incidence 
rates for small age categories is particular valuable 
information in the context of rotavirus vaccine safety 
surveillance since studies suggest that the risk of 
intussusception caused by rotavirus vaccine is primar-
ily in the first week after the first dose, administered 
in early childhood [6-11]. However, denominator data 
are not readily available and approximate denomina-
tors from population census data have to be used. 
In addition, case detection in this particular hospital 
database depends on the accuracy of coding and could 
not be validated. Published positive predictive values 
of ICD-9 codes for intussusception range from 75% to 
81%, and are even lower when including outpatient 
department data [34-36]. Therefore, the hospital data-
base estimates may be an overestimation of the true 
Table 3
Intussusception incidence rates in children < 36 months of age per 100,000 person-years based on validated cases from the 
IPCI database, the Netherlands, January 2003–December 2012
Sex and age
Time period
1 Jan 2003–31 Dec 2012 1 Jan 2008–31 Dec 2012
Incidence rate per 100,000 person-years 95% CI Incidence rate per 100,000 person-years 95% CI
Overall 20.2 12–32 21.3 12.5–34.3
Sex
Male 26.7 14.2–46.2 27.7 14.2–49.2
Female 12.7 4.8–27.9 14.6 5.5–32
Age
0–11 months 24.6 12.6–43.7 27.9 14.3–49.5
12–23 months 19.8 7.5–43.3 18 6.0–42.9
24–35 months 6.9 0.6–32 8.1 0.7–37.9
IPCI: Integrated Primary Care Information.
The IPCI database contains general practitioner medical records.
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incidence. Moreover, in contrast to the primary health-
care database, the intussusception cases derived from 
the hospital database may contain cases of transient 
intussusception, recurrent intussusception and/or 
suspected intussusception. In order to further investi-
gate the quality of the estimates derived from the LBZ 
database, a validation study could be considered. In 
the future, if hospital data are to be used for intussus-
ception surveillance, distinguishing suspected intus-
susception cases and transient intussusception cases 
from true intussusception cases might be of added 
value.
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